Victory Capital Management Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Victory Capital Management Inc. bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,152 shares of the company’s stock, valued at approximately $676,000.

Other institutional investors have also added to or reduced their stakes in the company. RA Capital Management L.P. bought a new position in shares of Dyne Therapeutics in the 1st quarter valued at about $140,666,000. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the period. Artal Group S.A. increased its position in Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after buying an additional 300,000 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in Dyne Therapeutics by 495.2% in the first quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after buying an additional 1,004,680 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The disclosure for this sale can be found here. Insiders sold a total of 22,868 shares of company stock valued at $796,760 over the last quarter. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Trading Up 0.5 %

NASDAQ DYN opened at $36.59 on Friday. The company has a market cap of $3.20 billion, a price-to-earnings ratio of -9.22 and a beta of 1.07. The company has a 50 day moving average of $41.07 and a 200-day moving average of $33.61. Dyne Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Morgan Stanley lifted their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.